Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias

NCT02580552 is registered in ClinicalTrials.gov with miRagen Therapeutics, Inc. as lead sponsor.

NCT NCT02580552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02580552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
Lead sponsor
miRagen Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 9, 2016
Completion date
October 6, 2020
Enrollment
66 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

adult t-cell leukemia/lymphoma (atll), chronic lymphocytic leukemia (cll), cutaneous t-cell lymphoma (ctcl), diffuse large b-cell lymphoma (dlbcl), abc subtype, mycosis fungoides (mf)